roduct Information: Svitinib 50mg Capsules
Svitinib 50mg Capsule is an orally active multi-targeted small-molecule tyrosine kinase inhibitor (TKI) containing Sunitinib Malate equivalent to 50mg of sunitinib.
1. Indications & Usage
Svitinib 50mg Capsules are indicated primarily under strict professional medical, clinical research, and specialist oncology supervision for:
Advanced Renal Cell Carcinoma (RCC): Prescribed for the systemic treatment of advanced or metastatic renal cell carcinoma.
Gastrointestinal Stromal Tumor (GIST): Indicated for the treatment of gastrointestinal stromal tumors after disease progression on or intolerance to imatinib mesylate.
Pancreatic Neuroendocrine Tumors (pNET): Administered for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.
2. Mechanism of Action: Multi-Kinase & Angiogenesis Inhibition
Sunitinib stops oncogenic cellular duplication and vascular blood supply tracking through precise target receptor blockade:
Simultaneous RTK Inhibition: Svitinib targets and binds to multiple receptor tyrosine kinases responsible for the propagation of cancer growth.
Angiogenesis Arrest: It actively restricts the growth of new blood vessels within the tumor matrix, starving abnormal cells of essential expansion signals.
Tumor Microenvironment Disruption: By blocking specific cell surface proteins and enzymes, it interrupts intracellular proliferation cascades to shrink the tumor and slow disease progression.
3. Storage, Stability & Commercial Packaging Specifications
Temperature Maintenance: Store in a dry, cool environment below 30°C.
Protect shipments from prolonged thermal spikes, moisture vapor transmission, and direct ambient ultraviolet sunlight. Commercial Integrity: Packed in standard heavy-duty foil blister setup configurations designed to maintain maximum stability during long-range transit variables.
Safety Protocol: Keep strictly out of the sight and reach of children.
Do not break, chew, or open the capsules.
4. Safety Profile, Side Effects, and Clinical Monitoring
Because Svitinib is a highly potent antineoplastic agent, ongoing specialist clinical monitoring is mandatory to protect patient safety.
Common Manifestations: Fatigue, diarrhea, nausea, stomatitis/mouth sores, dyspepsia, high blood pressure, and hand-foot syndrome.
Cardiovascular & Hematological Monitoring: Regular evaluation of blood pressure and cardiac safety parameters is strongly advised.
Routine complete blood counts (CBC) are required due to potential reduction in platelets, red blood cells, and white blood cells. Hepatic & Renal Supervision: Periodic liver and kidney function profiles must be carried out by a physician to safeguard against drug-induced toxicity.
5. Regulatory and Compliance Documentation
ERNEST IMPEX ensures that every trade lane shipment of Svitinib 50mg complies with strict international customs and medical export expectations by providing:
Comprehensive Commercial Invoice & Itemized Packing Lists
Validated Certificates of Analysis (CoA) from approved laboratories
Legalized Export Documentation (IEC & Custom shipping clearance data)
Secure, temperature-shielded freight layout for air or cargo routing
💡 Why Choose ERNEST IMPEX?
Direct sourcing channels from verified manufacturing infrastructure in India
Scale-ready capacity for hospital groups, clinical distributors, and regional wholesalers
Precision documentation routing for transparent customs tracking
Dedicated global trade desks providing end-to-end support
PRESCRIPTION MEDICINE: YES
Svitinib 50mg Capsules must be supplied and administered strictly under the authority of a registered professional. The clinical and pharmacological data listed here serves strictly as a commercial guide for international bulk procurement, regulatory compliance matching, and wholesale trade awareness.
📞 Contact Ernest Impex — Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
